Compare Glenmark Pharma with BROOKS LAB - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs BROOKS LAB - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA BROOKS LAB GLENMARK PHARMA/
BROOKS LAB
 
P/E (TTM) x 13.9 -16.8 - View Chart
P/BV x 2.0 3.8 53.4% View Chart
Dividend Yield % 0.5 0.0 -  

Financials

 GLENMARK PHARMA   BROOKS LAB
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-21
BROOKS LAB
Mar-21
GLENMARK PHARMA/
BROOKS LAB
5-Yr Chart
Click to enlarge
High Rs57378 737.1%   
Low Rs19516 1,220.6%   
Sales per share (Unadj.) Rs387.831.3 1,240.2%  
Earnings per share (Unadj.) Rs34.4-7.8 -438.4%  
Cash flow per share (Unadj.) Rs50.1-4.9 -1,012.3%  
Dividends per share (Unadj.) Rs2.500-  
Avg Dividend yield %0.70-  
Book value per share (Unadj.) Rs249.632.0 778.9%  
Shares outstanding (eoy) m282.1724.70 1,142.4%   
Bonus / Rights / Conversions ---  
Price / Sales ratio x1.01.5 66.1%   
Avg P/E ratio x11.2-6.0 -186.9%  
P/CF ratio (eoy) x7.7-9.5 -81.0%  
Price / Book Value ratio x1.51.5 105.2%  
Dividend payout %7.30-   
Avg Mkt Cap Rs m108,3531,157 9,362.3%   
No. of employees `000NANA-   
Total wages/salary Rs m23,437120 19,462.8%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m109,439772 14,167.4%  
Other income Rs m5027 6,822.8%   
Total revenues Rs m109,941780 14,098.3%   
Gross profit Rs m21,2895 408,623.0%  
Depreciation Rs m4,43671 6,209.6%   
Interest Rs m3,53131 11,398.1%   
Profit before tax Rs m13,825-90 -15,386.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m4,124104 3,972.1%   
Profit after tax Rs m9,701-194 -5,008.7%  
Gross profit margin %19.50.7 2,884.8%  
Effective tax rate %29.8-115.6 -25.8%   
Net profit margin %8.9-25.1 -35.4%  
BALANCE SHEET DATA
Current assets Rs m73,596503 14,625.0%   
Current liabilities Rs m42,010637 6,593.6%   
Net working cap to sales %28.9-17.3 -166.5%  
Current ratio x1.80.8 221.8%  
Inventory Days Days716 41.7%  
Debtors Days Days86647 13.3%  
Net fixed assets Rs m67,0931,118 6,003.6%   
Share capital Rs m282247 114.2%   
"Free" reserves Rs m70,148544 12,883.9%   
Net worth Rs m70,430791 8,898.5%   
Long term debt Rs m38,888144 26,930.9%   
Total assets Rs m140,6891,621 8,680.4%  
Interest coverage x4.9-1.9 -258.7%   
Debt to equity ratio x0.60.2 302.6%  
Sales to assets ratio x0.80.5 163.2%   
Return on assets %9.4-10.0 -93.7%  
Return on equity %13.8-24.5 -56.3%  
Return on capital %15.9-6.3 -252.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m35,7530-   
Fx outflow Rs m12,0230-   
Net fx Rs m23,7290-   
CASH FLOW
From Operations Rs m11,31245 25,369.2%  
From Investments Rs m-6,752-51 13,162.5%  
From Financial Activity Rs m-4,41812 -38,117.3%  
Net Cashflow Rs m2785 5,700.8%  

Share Holding

Indian Promoters % 46.7 66.4 70.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 35.0 0.0 -  
FIIs % 25.9 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 53.4 33.6 158.8%  
Shareholders   329,870 10,379 3,178.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   SAMRAT PHARMA  GENNEX LAB.  KIMIA BIOSCIENCES  ALCHEMIST LIMITED  PHAARMASIA  



Today's Market

SGX Nifty Trades Flat, Maruti Suzuki Results amid Chip Shortage, PolicyBazaar IPO, and Buzzing Stocks Today(Pre-Open)

Indian share markets ended on a negative note yesterday. After trading in a range throughout the session, benchmark indices slipped into red during closing hours.

Related Views on News

GLENMARK PHARMA 2020-21 Annual Report Analysis (Annual Result Update)

Sep 6, 2021 | Updated on Sep 6, 2021

Here's an analysis of the annual report of GLENMARK PHARMA for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY22); Net Profit Up 20.7% (Quarterly Result Update)

Aug 16, 2021 | Updated on Aug 16, 2021

For the quarter ended June 2021, GLENMARK PHARMA has posted a net profit of Rs 3 bn (up 20.7% YoY). Sales on the other hand came in at Rs 30 bn (up 26.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 132.5% (Quarterly Result Update)

Sep 1, 2020 | Updated on Sep 1, 2020

For the quarter ended June 2020, GLENMARK PHARMA has posted a net profit of Rs 3 bn (up 132.5% YoY). Sales on the other hand came in at Rs 23 bn (up 0.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 64.0% (Quarterly Result Update)

Feb 19, 2020 | Updated on Feb 19, 2020

For the quarter ended December 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 64.0% YoY). Sales on the other hand came in at Rs 27 bn (up 7.1% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 132.5% (Quarterly Result Update)

Sep 1, 2020 | Updated on Sep 1, 2020

For the quarter ended June 2020, GLENMARK PHARMA has posted a net profit of Rs 3 bn (up 132.5% YoY). Sales on the other hand came in at Rs 23 bn (up 0.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

More Views on News

Most Popular

Tata Group Stocks are on Fire: Which one Should You Buy?(Profit Hunter)

Oct 15, 2021

Tata group stocks are on fire. Find out which one deserves your attention.

India's Big PSU Selloff: Watch Out for these Top Stocks(Views On News)

Oct 15, 2021

The government's plan to divest its stakes in PSUs could spark off a rally in these four stocks.

Up 31,500% in a Year! This Packaging Company Sheds its Penny Stock Status(Views On News)

Oct 18, 2021

What's driving the relentless rally in this packaging company?

Insider Alert! Promoters are Increasing their Stakes in these 5 Companies(Views On News)

Oct 19, 2021

Promoters of many small and mid-cap companies are raising their stakes since the last few quarters.

The One Company Riding the Auto Revolution Beyond EVs(Profit Hunter)

Oct 22, 2021

It's not just about batteries taking over the internal combustion engine. Bigger disruptive forces are coming along with electrification.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Oct 27, 2021 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 5-YR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS